5.47 USD
▲+0.04+0.74%
盘后 5.46 -0.18%
2026-09-15
市值
$307.08M
市盈率
6.94
EPS
-1.18
股息率
—
52 周区间
4.00 – 7.65
成交量
1.93M
Beta
1.32
目标价
18.86
52W 低 4.0052W 高 7.65
价格走势
公司简介
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor...